Research Article
[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
Table 4
Distribution of patients with HBeAg <0.5PEIU/mL and anti-HBe (+) at different time periods.
| Indicators (months) | Control group (n = 26) | Tenofovir group (n = 26) | Entecavir group (n = 26) |
| 3 | 5 (19.23%) | 13 (50.00%)#& | 10 (38.46%)# | 6 | 8 (30.77%)∗ | 17 (65.38%)∗#& | 14 (53.85%)∗# | 12 | 10 (38.46%)∗@ | 21 (80.77%)∗@#& | 18 (69.23%)∗@# |
|
|